At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 274 enrolled
Drug / intervention
Testosterone (T) Gel 1.62% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind,Placebo-Controlled Efficacy and Safety Study of Testosterone Gel 1.62% for the Treatment of Hypogonadal Men
In Brief
A Phase 3 clinical trial evaluating Testosterone (T) Gel 1.62% and Placebo for Hypogonadism. Completed, enrolled 274 participants.
Detailed Summary
Demonstrate efficacy and safety of Testosterone Gel 1.62% for the treatment of hypogonadal men
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedFeb 2007
Primary CompletionOct 2007
Study CompletionApr 2008
TodayJul 2026
First PostedFeb 9, 2007
Enrollment StartFeb 1, 2007
Primary CompletionOct 1, 2007
Study CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 19.4 years ago
Interventions
Testosterone (T) Gel 1.62%drug
Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
Placebodrug
Placebo Control